Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer (ERACLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01303926
Recruitment Status : Unknown
Verified April 2012 by Giuseppe Colucci MD, Gruppo Oncologico Italia Meridionale.
Recruitment status was:  Active, not recruiting
First Posted : February 25, 2011
Last Update Posted : April 10, 2012
Information provided by (Responsible Party):
Giuseppe Colucci MD, Gruppo Oncologico Italia Meridionale

Brief Summary:
Cisplatin and pemetrexed combination or carboplatin, paclitaxel and bevacizumab are now considered as standard treatment in non-squamous cell lung carcinoma (NSCLC). Both main registrative trials are considered positive because they reached their objectives, but within them, the Quality of Life (QoL) of patients was not detailed neither has represented as primary objective of the studies. It is considered that, together with enhancements that are added to the knowledge of the biology of NSCLC, QoL may influence the therapeutic choice if one of the associations show to be better tolerated by the patient and favours an amelioration of his QoL.

Condition or disease Intervention/treatment Phase
Non-squamous Nonsmall Cell Neoplasm of Lung Drug: cisplatin pemetrexed Drug: carboplatin paclitaxel bevacizumab Phase 3

Detailed Description:

The study aims primarily to verify the null hypothesis that between the two schemes under consideration there is no minimal interesting difference (MID) (i.e. a difference of clinical interest) after initial 3 months of maintenance.EuroQ5D (EQ5D) questionnaire total score and EQ5D visual analog scale (VAS)are validated and very simple to be administered.The statistical hypothesis tests described above are performed with t-test for unpaired data (or equivalent non-parametric, pending verification of normality of distribution by Shapiro-Wilk test), with alpha error = 0.05 (2-sided). It is assumed that:

  1. about 20% of randomized patients experienced a progression of disease before the time of evaluation of the primary endpoint, and that
  2. this eventuality was not significantly different between the two treatments. The total sample to be enrolled for this study will then be increased to 118 patients [(49 +49) +20%)]

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM
Study Start Date : January 2010
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Active Comparator: Cisplatin and Pemetrexed Drug: cisplatin pemetrexed
Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity

Active Comparator: Carboplatin paclitaxel bevacizumab Drug: carboplatin paclitaxel bevacizumab
Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity

Primary Outcome Measures :
  1. Difference in terms of quality of life (QOL) between treatment arms [ Time Frame: Treatment efficacy will be evaluated at baseline and every 3 cycles during chemo period and every two months during the maintenance phase ]

Secondary Outcome Measures :
  1. treatment activity in terms of response rate [ Time Frame: Two year ]
  2. toxicity evaluation [ Time Frame: Two years ]
  3. Evaluation of QoL across time [ Time Frame: Two years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent(as approved by the local Ethical Committee)
  • Histological type consisting mainly of non-squamous histology defined preferably with stage IV metastatic disease or stage IIIB in the presence of supraclavicular lymph nodes according to the parameters of TNM 7th Ed, not amenable to curative therapy
  • ECOG PS 0-1
  • Adequate bone marrow reserve
  • Adequate hepatic, coagulative and renal function

Exclusion Criteria:

  • Mixed NSCLC tumors or mixed adenosquamous carcinomas with a predominant squamous component histotype (NSCLC and SCLC) or adenosquamous forms, with predominant squamous component
  • History of gross hemoptysis <3 months prior to enrollment or history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
  • Tumors invading or abutting major blood vessels (based on radiologist assessment)
  • Evidence of brain metastases not previously treated with RT (or any loco-regional treatment)
  • Prior neoadjuvant or adjuvant chemotherapy within six months prior to study enrollment
  • Previous radiotherapy in the last month before study entry (except for radiotherapy to symptomatic bone sites at risk and not covered in the premises of measurable disease and assessable)
  • A major surgery (including open biopsy) in the month preceding study enrollment or anticipation of a major surgery during the study
  • Unable or unwilling to take folic acid or vitamin B12 supplementation
  • Unable or unwilling to take corticosteroids
  • History of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis
  • Clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
  • Need for taking or have recently taken (within 10 days of enrollment) aspirin (>325 mg/d), clopidogrel at doses >75 mg/d, dipyramidole, ticlopidine, or cilostazol. Patients are also excluded if they cannot hold nonsteroidal anti-inflammatory agents, other than prophylactic therapy with low-dose aspirin, for a 5-day period during each cycle (8-day period for long-acting agents, such as piroxicam)
  • Need for taking or have recently taken (within 10 days of enrollment) fulldose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes. Prophylactic use of anticoagulants is allowed; international normalized ratio (INR) should be <1.5 at study enrollment
  • History of thrombotic disorders within the last 6 months prior to entry History of hypertension, unless hypertension is well controlled study entry (≤150/90 mm Hg) and the patient is on a stable regimen of antihypertensive therapy. Patients should not have any prior history of hypertensive crisis or hypertensive encephalopathy
  • Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV
  • Serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol
  • Receiving concurrent administration of any other antitumor therapy
  • Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment
  • Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score ≤6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously
  • Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01303926

Layout table for location information
"Giovanni Paolo II" Oncology Institute
Bari, BA, Italy, 70124
"San Paolo Hospital" Oncology Service
Bari, BA, Italy
Division of Medical Oncology, "Fatebenefratelli" Hospital
Benevento, BN, Italy
Division of Medical Oncology, "Sen. Perrino" Hospital, Brindisi, Italy
Brindisi, BR, Italy, 72100
7 Division of Medical Oncology, "Casa Sollievo della Sofferenza" Hospital,
San Giovanni Rotondo, FG, Italy
Medical Oncology Division "Vito Fazzi" Hospital
Lecce, Le, Italy
Division of Medical Oncology, "Buccheri-La Ferla" Hospital
Palermo, PA, Italy
Division of Medical Oncology, "La Maddalena" Hospital
Palermo, PA, Italy
Division of Medical Oncology, Castellaneta Hospital
Castellaneta, TA, Italy
Division of Medical Oncology "San Giuseppe Moscati Hospital"
Taranto, TA, Italy
Clinical Trials Office, Department of Medical Sciences, Azienda ULSS 13
Mirano, VE, Italy
National Cancer Institute "G. Pascale" Thoracic Dept.
Napoli, Italy
Sponsors and Collaborators
Gruppo Oncologico Italia Meridionale
Layout table for investigator information
Principal Investigator: Giuseppe Colucci, MD Oncology Institute of Bari
Study Director: Domenico Galetta, MD "Giovanni Paolo II" Oncology Instutute Medical Oncology Dept. Bari (Italy)
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Giuseppe Colucci MD, President, Gruppo Oncologico Italia Meridionale Identifier: NCT01303926    
Other Study ID Numbers: Goim 2903
2009-015807-19 ( EudraCT Number )
First Posted: February 25, 2011    Key Record Dates
Last Update Posted: April 10, 2012
Last Verified: April 2012
Keywords provided by Giuseppe Colucci MD, Gruppo Oncologico Italia Meridionale:
EQ5D score
cisplatin pemetrexed
carboplatin paclitaxel bevacizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors